Research institution
Shanghai Pulmonary Hospital, Shanghai, China Clinical Trials
Studies where Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 73Relapsed Small Cell Lung Cancer (SCLC)
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer.
- Trial name
- NCT07874581
- Testing
- MRG003 (Becotatug Vedotin)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
ALK, NSCLC
Neoadjuvant Iruplinalkib and Bevacizumab in ALK-positive NSCLC: A Phase II Single-arm Trial
This is a single-center, single-arm, prospective phase II trial evaluating iruplinalkib plus bevacizumab as neoadjuvant therapy in ALK-positive NSCLC.
- Conditions
- ALK, NSCLC, Neoadjuvant Therapy
- Trial name
- NCT07870733
- Testing
- Bevacizumab combined with iruplinalkib as neoadjuvant therapy in ALK-positive NSCLC:
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Locally Advanced Non-Small Cell Lung Cancer
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
Surgical intervention remains the primary treatment option for early-stage lung cancer. With the proven efficacy of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), neoadjuvant immunotherapy has…
- Trial name
- NCT07863999
- Testing
- PD-L1/VEGF Bispecific Antibody, PD-1 Monoclonal Antibody, Nab-paclitaxel
- Where
- 5 sites in China
- Volunteers
- 290 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
This prospective, real-world observational study (T2AIR Study) evaluates the long-term efficacy and safety of six biologics targeting Type 2 inflammation - omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and…
- Trial name
- T2AIR (NCT07823842)
- Testing
- Biologics targeting Type 2 inflammation, Patients with asthma and copd who received standard of care
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances.
- Trial name
- NCT07820254
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC (Non-small Cell Lung Cancer)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
his multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body…
- Trial name
- NCT07754812
- Testing
- Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Residual Neuromuscular Block
Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function
Residual neuromuscular blockade (NMB) after general anesthesia increases the risk of postoperative respiratory complications (atelectasis, pneumonia, re-intubation) and delays pulmonary function recovery.
- Trial name
- NCT07309393
- Testing
- Sugammadex, Neostigmine
- Where
- 3 sites in China
- Volunteers
- 240 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and…
- Conditions
- Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
- Trial name
- NCT07608159
- Testing
- Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy
- Volunteers
- 201 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-Small-Cell Lung Cancer, Neoadjuvant Therapy
Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial
This study is a multicenter, single-arm Phase II clinical trial, aiming to explore the safety and preliminary efficacy of oral paclitaxel solution combined with immune checkpoint inhibitors as a neoadjuvant regimen in elderly…
- Conditions
- Non-Small-Cell Lung Cancer, Neoadjuvant Therapy, Paclitaxel
- Trial name
- NCT07599163
- Testing
- Paclitaxel Oral Solution
- Volunteers
- 75 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Pulmonary Nodules, Early-Stage Lung Cancer
Application of Electromagnetic Navigation System in Pulmonary Nodule Localization
This study aims to design and conduct a multicenter, prospective, randomized controlled post-market clinical trial to validate the clinical efficacy of high-precision electromagnetic navigation technology.
- Trial name
- NCT07595120
- Testing
- Electromagnetic Navigation-Guided Percutaneous Localization of Pulmonary Nodules, CT-Guided Percutaneous Localization of Pulmonary Nodules
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Completed, with results posted
All 1Bronchiectasis
Assessment of an Exhaled Breath Test to Detect Bronchiectasis
To investigate whether the breath test is able to detect bronchiectasis using breathomics. This study was conducted with a prospective specimen collection, evaluator-blinded, case-controlled clinical study designed to evaluate…
- Trial name
- NCT05293314
- Testing
- An exhaled breath test
- Where
- China
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China